ScholarLens Back to search
2021•NeurologyRequires access

Long-term efficacy and safety of eculizumab monotherapy in AQP4+ neuromyelitis optica spectrum disorder (1578)

Sean J. Pittock, Kazuo Fujihara, Jacqueline Palace, Achim Berthele, Ho Jin Kim, Celia Oreja Guevara, Ichiro Nakashima, Michael Levy, Shulian Shang, Marcus Yountz, Larisa Miller, Róisín Armstrong, Dean M. Wingerchuk

Open publisher page 1 citations

Abstract

To examine the long-term efficacy and safety of eculizumab monotherapy in patients with aquaporin-4 immunoglobulin G-positive (AQP4+) neuromyelitis optica spectrum disorder (NMOSD) during PREVENT and/or its ongoing open-label extension (OLE).

About this research paper

What this paper is about

To examine the long-term efficacy and safety of eculizumab monotherapy in patients with aquaporin-4 immunoglobulin G-positive (AQP4+) neuromyelitis optica spectrum disorder (NMOSD) during PREVENT and/or its ongoing open-label extension (OLE).

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

To examine the long-term efficacy and safety of eculizumab monotherapy in patients with aquaporin-4 immunoglobulin G-positive (AQP4+) neuromyelitis optica spectrum disorder (NMOSD) during PREVENT and/or its ongoing open-label extension (OLE).

Key concepts: Eculizumab, Neuromyelitis optica, Spectrum disorder, Medicine, Broad spectrum, Dermatology, Pediatrics, Antibody

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Long-term efficacy and safety of eculizumab monotherapy in AQP4+ neuromyelitis optica spectrum disorder (1578) — Research Paper | ScholarLens